Tag:

Merck

Latest Headlines

Latest Headlines

New numbers back old meme: Pharma does spend more on marketing than R&D

The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.

Merck to meat industry: Zilmax is safe

After Merck's feed additive Zilmax was pulled from the market on side effect concerns last year, the company embarked on a comprehensive review. The results are in, and Merck has concluded the product is safe when consumed as detailed on the label.

UPDATED: Merck partners with Bind on a pair of new cancer drug programs

Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.

Zilmax is safe, Merck says. But will the meat industry buy it?

When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After a comprehensive review, the drugmaker has determined the product is safe when used according to its label. Now it just has to convince the meat-packing industry.

Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs

A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.

Pharma's top 10 M&A deals of 2014's first half

Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of...

Merck bogged down by slumping sales, but cuts deliver on profits

It has been a roller-coaster ride of a year for Merck, complete with M&A and corporate bloodletting intended to swing the company's numbers northward. Part of the drugmaker's ongoing turnaround plan could be paying off, as Merck announced third quarter earnings that beat analysts' expectations. But the company also reported slumping sales of some of its standout products due to hep C competitors and patent expirations, signaling more work in the months to come.

Merck grabs another 'breakthrough' in PD-1 lung cancer race with Bristol-Myers

With the goal line for lung cancer in sight at the FDA as it races with an ambitious R&D team at Bristol-Myers Squibb, Merck has grabbed bragging rights to the agency's breakthrough drug designation for the checkpoint inhibitor pembrolizumab (Keytruda) for that golden market opportunity.

Are flea-fighting pills gaining ground on OTC topicals?

PetMed Express CEO Menderes Akdag raised a few eyebrows when he blamed his company's missed quarterly profit and sales targets on the weather.

FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine

Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.